Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: an open pilot study. Issue 6 (1st June 2000)

• Record Type: Journal Article
• Authors: Van den Bosch, Filip; Kruithof, Elli; Baeten, Dominique; De Keyser, Filip; Mielants, Herman; Veys, Eric M
• Is Part Of: Annals of the rheumatic diseases. Volume 59:Issue 6(2000)
• Page Start: 428
• Page End: 433
• Publication Date: 2000-06-01
• Subjects: spondyloarthropathy -- ankylosing spondylitis -- psoriatic arthritis -- anti-TNFα; Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/ard.59.6.428
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : OBJECTIVE: To evaluate the efficacy and safety of a loading dose regimen of three intravenous infusions with infliximab in patients with active spondyloarthropathy. METHODS: A monocentre, open-label pilot study of 21 patients with different subtypes of spondyloarthropathy was conducted. Treatment resistant patients with active disease (fulfilling inclusion criteria) received three infusions of 5 mg/kg infliximab (at weeks 0, 2, and 6). Standard clinical assessments were performed at baseline, and on days 3, 7, and 14, and from then on every two weeks. In patients who fulfilled criteria for ankylosing spondylitis, axial assessment was performed at baseline and on days 14, 42, and 84. RESULTS: In all global assessments (visual analogue scale of patient global assessment, patient pain assessment, doctor global assessment), erythrocyte sedimentation rate, and C reactive protein, a highly significant decrease could be seen already at day 3 (compared with baseline), which was maintained up to day 84. In patients with peripheral disease (n=18), tender and swollen joint count significantly decreased. In patients with axial disease (n=11), functional and disease activity indices significantly improved. Moreover in eight patients with psoriatic arthritis a significant decrease of the psoriasis area and severity index was observed. The treatment was well tolerated in all patients; no significant adverse events were seen. CONCLUSION: In this open-label pilot study of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α in patients with active spondyloarthropathy, there was a fast and significant improvement of axial and peripheral articular manifestations, without major adverse experiences.